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Background: Cicletanine is an antihypertensive agent with vasorelaxant and diuretic
properties. It has been widely used in European countries; however, cicletanine-
associated electrolyte disturbances have yet to be deﬁned. We investigated
cicletanine-induced hyponatremia and hypokalemia in kidney transplant patients.
Methods: Data from a total of 68 kidney transplant recipients who were treated for
hypertension with cicletanine were retrospectively analyzed. Cicletanine-induced
hyponatremia and hypokalemia were deﬁned as serum sodium < 135 mmol/L and
potassium < 3.5 mmol/L, respectively, after the use of cicletanine.
Results: The average patient age was 50 (±11) years, and 44 (65%) were male. The
daily dose of cicletanine was 171 ± 46 mg, and the duration of drug use was
215 ± 514 days. Hyponatremia occurred in 11 patients (16.2%), and hypokalemia
occurred in 8 patients (11.8%). Three patients (4.4%) had hyponatremia and hypo-
kalemia simultaneously. The duration of cicletanine administration was signiﬁcantly
longer in patients with hyponatremia than in those without hyponatremia
(943 ± 958 vs. 74 ± 166 days, P < 0.05). The occurrence of hypokalemia was not
affected by either daily dose or duration of drug use. Among 11 patients with
hyponatremia, 10 were corrected within 2 weeks after withdrawal of the drug and 1
was spontaneously corrected. Among 8 cases of hypokalemia, 7 were corrected after
withdrawal of the drug and 1 was spontaneously corrected.
Conclusion: We demonstrate that cicletanine may induce hyponatremia or hypo-
kalemia in kidney transplant patients. Hyponatremia is more frequently associated
with cicletanine than hypokalemia, and extended use of cicletanine may increase
the risk of hyponatremia.
Copyright © 2016. The Korean Society of Nephrology. Published by Elsevier. This is
an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).rnal Medicine, Hanyang
simni-ro, Seongdong-gu,
).
ntributed equally to this
ty of Nephrology. Published b
/4.0/).Introduction
Kidney transplant patients frequently have hypertension
irrespective of their native kidney diseases. It is important to
control blood pressure after kidney transplantation (KT)
because uncontrolled hypertension is associated with earlier
graft failure and higher cardiovascular mortality in the re-
cipients [1]. Notably, salt sensitivity has a role in the patho-
genesis of hypertension associated with chronic kidney disease
(CKD) [2] and the use of calcineurin inhibitors [3]. Thus, diureticy Elsevier. This is an open access article under the CC BY-NC-ND license
Table 1. General characteristics of patients (n ¼ 68)
Demographic proﬁle
Age (y) 50.0 ± 11.0
Sex (male) 44 (65)
Body mass index (kg/m2) 23.4 ± 3.9
Period after kidney transplantation (mo) 157 ± 57
Comorbidities
Diabetes mellitus 6 (8.8)
Dyslipidemia 25 (36.8)
Malignancy 6 (8.8)
Concurrent medications (n)
ACE inhibitors 18
ARBs 16
Beta blockers 6
Calcium channel blockers 28
Loop diuretics 6
Baseline laboratory data
Serum sodium (mmol/L) 142 ± 2
Serum potassium (mmol/L) 4.3 ± 0.5
Serum chloride (mmol/L) 105 ± 4
Total CO2 (mmol/L) 24.5 ± 4.2
BUN (mg/dL) 30.7 ± 14.6
Serum creatinine (mg/dL) 2.0 ± 1.3
eGFR* (mL/min/1.73 m2) 44.7 ± 21.7
Uric acid (mg/dL) 7.6 ± 1.7
Data are presented as mean ± SD or n (%).
* eGFR was calculated using the Chronic Kidney Disease
Epidemiology Collaboration equation.
ACE, angiotensin-converting enzyme; ARBs, angiotensin receptor
blockers; BUN, blood urea nitrogen; eGFR, estimated glomerular ﬁltra-
tion rate.
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transplant recipients.
Cicletanine (Tenstaten; Daewoong, Seoul, Korea) is an anti-
hypertensive agent, synthetized by Esanu et al in 1986, and has
been widely used in European countries [4]. It has been
commercially available in Korea since 1992 and is used for the
treatment of hypertension because it has effects of natriuresis
and vasodilation without reﬂex tachycardia [5]. Although previ-
ous studies reported on the efﬁcacy and safety of cicletanine in
the treatment of hypertension [6,7], adverse effects of electrolyte
imbalance induced by cicletanine have yet to be investigated.
Considering that the action of cicletanine is associated with
natriuresis and kaliuresis [8], we postulated that cicletanine
may produce side effects of hyponatremia and hypokalemia
similar to those of thiazide diuretics. A few previous studies
have shown that cicletanine has a milder natriuretic effect [9]
and less kaliuresis [8] than thiazide diuretics in a small num-
ber of patients with essential hypertension. However, whether
hyponatremia and hypokalemia are induced by cicletanine has
not been investigated in patients with CKD. This study was
undertaken to characterize cicletanine-induced hyponatremia
and hypokalemia in kidney transplant patients.
Methods
We conducted a retrospective analysis of adult patients who
underwent KT in Hanyang University Seoul Hospital and were
prescribed cicletanine >2 weeks for the treatment of hyper-
tension from January 2001 to April 2008. The patients who
returned to hemodialysis or peritoneal dialysis after KT were
excluded. We also excluded patients whose serum sodium and
potassium levels were previously lower than 135 and
3.5 mmol/L, respectively.
Laboratory data, including serum electrolytes, blood urea ni-
trogen (BUN), and serum creatinine before and after cicletanine
administration, were reviewed. To evaluate patient characteris-
tics, demographic data including comorbidities and concurrent
medications were also collected. The dose and duration of
cicletanine use were estimated. Estimated glomerular ﬁltration
rate (eGFR) was calculated using the Chronic Kidney Disease
Epidemiology Collaboration equation.
Cicletanine-induced hyponatremia and hypokalemia were
deﬁned as having follow-up serum sodium concentration of
< 135 mmol/L and serum potassium concentration of
< 3.5 mmol/L. Accordingly, the incidence of cicletanine-induced
hyponatremia and hypokalemia was estimated. To compare
patient characteristics, patientswere divided into thosewith and
without cicletanine-induced hyponatremia or hypokalemia.
Data are expressed as mean ± standard deviation or fre-
quency (and proportion). Two groups were compared using the
ManneWhitney U test for continuous variables and the chi-
square test for categorical variables. Two-tailed P < 0.05 was
considered statistically signiﬁcant. All statistical analyses were
performed using StatView software (version 5.0 for Windows;
SAS Institute Inc., Cary, USA).
Results
General characteristics of patients prescribed cicletanine
Atotal of 68patientswere included in this study: 44men(65%)
and 24 women (35%). The mean age was 50 ± 11 years, and KTduration before cicletanine administrationwas 157 ± 57months.
Concurrent antihypertensives comprised angiotensin-converting
enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs),
calcium channel blockers, beta antagonists, loop diuretics, and
potassium-sparing diuretics. Forty-nine patients (72%) were
concurrentlymedicated,with calciumchannel blockers being the
most commonmedication (n ¼ 28, 41%).
The laboratory data obtained before cicletanine adminis-
tration are shown in Table 1; the serum sodium level was
142 ± 2 mmol/L, and the serum potassium level was
4.3 ± 0.5 mmol/L. The serum creatinine level ranged from 0.8 to
5.6 mg/dL. The average daily prescribed dose of cicletanine was
171 ± 46 mg, and the duration of cicletanine administration
was 215 ± 514 days, leading to a mean cumulative dose of
33 ± 68 g$days.Cicletanine-induced hyponatremia
Table 2 summarizes the number of patients with and
without electrolyte disturbances. Eleven patients (16.2%) had
cicletanine-induced hyponatremia; the serum sodium level
was decreased to 129 ± 4 mmol/L. Among them, 3 patients
(4.4%) had hyponatremia and hypokalemia simultaneously.
Hyponatremia was mild in 9 patients (82%, 126e134 mmol/L)
and severe in 2 patients (18%, 125 mmol/L). Two severe
hyponatremia patients and 6 of 9 mild hyponatremia patients
had their serum sodium concentration improved by discon-
tinuation of cicletanine. In contrast, hyponatremia was spon-
taneously corrected in 3 patients whose hyponatremia was
relatively mild (132e133 mmol/L) despite continued use of
cicletanine. Among them, however, hyponatremia recurred in 2
patients (66%).
Table 2. Number of patients with and without electrolyte
disturbances
Hyponatremia No hyponatremia Total
Hypokalemia 3 5 8
No hypokalemia 8 52 60
Total 11 57 68
Table 4. Data comparison between patients with and without
cicletanine-induced hypokalemia
Hypokalemia
(n ¼ 8)
No hypokalemia
(n ¼ 60)
P
Age (y) 56.6 ± 13.1 49.2 ± 10.5 0.116
Sex (M/F, n) 5/3 39/21 0.890
Body mass index (kg/m2) 21.9 ± 2.3 23.6 ± 4.0 0.261
Serum sodium (mmol/L) 134 ± 6 138 ± 4 0.100
Serum potassium (mmol/L) 3.2 ± 0.1 4.1 ± 0.5 < 0.001
Serum chloride (mmol/L) 99 ± 6 105 ± 6 < 0.001
Total CO2 (mmol/L) 23.6 ± 4.0 21.4 ± 5.5 0.336
BUN (mg/dL) 30.5 ± 15.5 33.9 ± 18.5 0.682
Serum creatinine (mg/dL) 2.1 ± 1.5 2.0 ± 1.2 0.864
Serum uric acid (mg/dL) 7.1 ± 3.3 7.6 ± 1.5 0.594
Serum total protein (g/dL) 6.3 ± 0.8 6.6 ± 0.8 0.291
Serum albumin (g/dL) 3.7 ± 0.6 4.0 ± 0.5 0.309
Serum glucose (mg/dL) 84.5 ± 11.1 89.3 ± 15.3 0.511
Daily dose (mg) 200.0 ± 0.0 166.7 ± 47.5 0.128
Duration of administration
(d)
375 ± 523 193 ± 513 0.435
Data are presented as mean ± SD.
BUN, blood urea nitrogen.
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with and without cicletanine-induced hyponatremia, there
were no signiﬁcant differences in age, sex, body mass index
(BMI), comorbidities, concurrent antihypertensives, serum
creatinine, serum uric acid, and daily dose of cicletanine.
However, patients with hyponatremia had signiﬁcantly lower
levels of serum total protein and albumin than those without
hyponatremia (Table 3). The duration of cicletanine adminis-
tration was signiﬁcantly longer in patients with hyponatremia
than in those without hyponatremia (943 ± 958 vs.
74 ± 166 days, P < 0.05).
Cicletanine-induced hypokalemia
Cicletanine-induced hypokalemia occurred in 8 patients
(11.8%), and all these patients had mild hypokalemia
( 3.0 mmol/L); the serum potassium level was decreased to
3.2 ± 0.1 mmol/L. All 3 patients who had hypokalemia and
hyponatremia simultaneously recovered after cicletanine
withdrawal, and 5 patients with only hypokalemia improved
without discontinuing cicletanine. However, 4 of these 5 pa-
tients had recurrent hypokalemia and had to discontinue
cicletanine for complete recovery.
When patient characteristics were compared between those
with and without cicletanine-induced hypokalemia, therewere
no signiﬁcant differences in age, sex, body mass index,
comorbidities, concurrent antihypertensives, serum creatinine,
serum albumin, serum uric acid, and daily dose of cicletanine
(Table 4). Although serum chloride was signiﬁcantly lower in
patients with hypokalemia than in those without hypokalemia
(99 ± 6 vs.105 ± 6mmol/L, P < 0.05), the increase in serum total
CO2 was not statistically signiﬁcant (24 ± 4 vs. 21 ± 6 mmol/L).Table 3. Data comparison between patients with and without
cicletanine-induced hyponatremia
Hyponatremia
(n ¼ 11)
No hyponatremia
(n ¼ 57)
P
Age (y) 50.3 ± 13.7 49.9 ± 10.6 0.677
Sex (M/F, n) 6/5 38/19 0.441
Body mass index (kg/m2) 24.0 ± 6.2 23.2 ± 3.3 0.848
Serum sodium (mmol/L) 129 ± 4 139 ± 2 < 0.001
Serum potassium
(mmol/L)
3.9 ± 0.5 4.0 ± 0.6 0.484
Serum chloride (mmol/L) 98 ± 8 106 ± 4 < 0.001
Total CO2 (mmol/L) 18.2 ± 4.3 22.3 ± 5.4 0.019
BUN (mg/dL) 35.5 ± 17.5 33.1 ± 18.4 0.583
Serum creatinine (mg/dL) 2.4 ± 1.5 1.9 ± 1.2 0.594
Serum uric acid (mg/dL) 6.8 ± 4.7 7.7 ± 2.8 0.128
Serum total protein (g/dL) 5.9 ± 0.9 6.8 ± 0.7 0.005
Serum albumin (g/dL) 3.6 ± 0.5 4.0 ± 0.5 0.028
Serum glucose (mg/dL) 87 ± 12 89 ± 15 0.784
Daily dose of cicletanine
(mg)
172.7 ± 46.7 170.2 ± 46.2 0.894
Duration of cicletanine
use (d)
943 ± 958 74 ± 166 < 0.001
Data are presented as mean ± SD.
BUN, blood urea nitrogen.Discussion
In this study, we demonstrated that cicletanine induced
hyponatremia and hypokalemia while it was used for the
treatment of hypertension in kidney transplant patients.
Hyponatremia was more frequently associated with cicletanine
than hypokalemia, and extended use of cicletanine may in-
crease the risk of hyponatremia.
The mechanisms of action by which cicletanine exerts
antihypertensive effects are unclear. However, one possibility is
a direct action on the vascular wall because cicletanine, a
furopyridine-derivative drug, is believed to stimulate the syn-
thesis of prostaglandin I2 (also called prostacyclin) [5] and
inhibit sympathetic nerve activity [10]. Another possibility is
the natriuretic activity of the drug, resulting from the action of
the sulfoconjugated metabolite of cicletanine [4].
Whether cicletanine acts like thiazide diuretics in the distal
convoluted tubule is controversial. According to Greven [11],
cicletanine has a tubular site of action similar to thiazide di-
uretics, so despite the disparity in chemical structure between
these drugs, there is speculation that cicletanine has adverse
effects similar to thiazides. However, Monroy et al [12]
demonstrated that the natriuretic metabolite of cicletanine
(cicletanine sulfate) was unable to inhibit thiazide-sensitive
NaCl cotransporters in the distal convoluted tubule. Cicleta-
nine may act on different transporters than those targeted by
thiazides, such as the apical Naþ-dependent Cl/HCO3 anion
exchanger in the distal convoluted tubule [4]. Thus, cicletanine
may not act like thiazide diuretics.
Despite these pharmacologic clues, clinical studies on elec-
trolyte disorders induced by cicletanine were not previously
reported. According to Tarrade et al [6], hematologic and
biochemical values are not affected by cicletanine. Adverse ef-
fects reported during the use of cicletanine were gastrointes-
tinal disorders, fatigue, pruritus, headache, vertigo, and lower
limb edema, so it was concluded that cicletanine had no toxic or
serious adverse effects. Passa [13] reported that cicletanine
administered at 150e200 mg/d did not signiﬁcantly inﬂuence
serum sodium and potassium levels.
However, the ability to concentrate or dilute urine is
diminished in CKD, ultimately leading to changes in the serum
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susceptible to hyponatremia, especially when thiazide-like di-
uretics are administered.
In this study, hyponatremia occurred in 11 patients (16.2%)
among 68 kidney transplant recipients who used cicletanine
for the treatment of hypertension. We believe that a causative
relationship was present between hyponatremia and use of
cicletanine because hyponatremia appeared after using cicle-
tanine and was relieved by the discontinuance of the drug. The
incidence of cicletanine-induced hyponatremia that we
observed appears to be similar to that of thiazide-induced
hyponatremia, although previous studies have shown variable
incidences of thiazide-induced hyponatremia. Gross et al [15]
reported an estimated incidence of 11% in 114 elderly pa-
tients. According to Clayton et al [16], the incidence was 13.7%
in 951 adult patients. Interestingly, a population-based study
reported a higher prevalence (32.4%) of thiazide-associated
hyponatremia [17].
In comparison with hyponatremia, cicletanine-induced hy-
pokalemia in our patients was less frequent (11.8%) and milder
in severity. The association between hypokalemia and use of
cicletanine was also clear. The simultaneous occurrence of
hyponatremia and hypokalemia suggests that the diuretic
property of cicletanine induces natriuresis and kaliuresis.
Consistently, Wagner et al [8] reported that both hydrochlo-
rothiazide and cicletanine had more natriuretic, diuretic, and
kaliuretic effects than placebo. However, they showed that
150 mg of cicletanine had less kaliuresis than 25 mg of hy-
drochlorothiazide, a ﬁnding that is compatible with our results.
According to Singer et al [9], cicletanine has milder natriuretic
effects than thiazides and is relatively safer than thiazides with
lower risk of developing hypokalemia. These ﬁndings suggest
that cicletanine is a favorable and well-tolerated option for the
treatment of hypertension, compared to hydrochlorothiazide
[8,9].
Advanced age, female gender, and low body weight were
known to be risk factors of thiazide-induced hyponatremia
[16,18]. However, these factors were not signiﬁcantly associated
with cicletanine-induced hyponatremia in our study. As ex-
pected, patients with hyponatremia had a longer duration of
cicletanine administration. It is not clear why patients with
cicletanine-induced hyponatremia had lower levels of serum
protein than those without hyponatremia. In patients with
cicletanine-induced hypokalemia, the serum chloride level was
decreased, most likely due to hypokalemic metabolic alkalosis.
However, we did not ﬁnd that the serum total CO2 level was
signiﬁcantly different between patients with and without
hypokalemia.
This study has limitations because it involved clinical data
from a small number of patients that were retrospectively
analyzed. The chance of observation may increase in parallel
with the duration of medication. Only some of the patients had
urine electrolyte data, but they were all compatible with
diuretic-induced hyponatremia and hypokalemia [19,20]. We
excluded patients who had histories of electrolyte imbalance
before cicletanine administration. Importantly, most of our
patients with cicletanine-induced hyponatremia and hypoka-
lemia recovered within 2 weeks of discontinuation of the drug
(17 of 19 patients, 89.5%).
In conclusion, we documented cicletanine-induced hypo-
natremia and hypokalemia in kidney transplant patients. To the
best of our knowledge, there have been no clinical studies oncicletanine-associated electrolyte disorders. It may be empha-
sized that patients using cicletanine need to be monitored for
electrolyte disturbance as in cases with thiazide diuretic use.
Further studies are required to determine conclusively whether
cicletanine induces hyponatremia or hypokalemia in other
scenarios of CKD and in a population with normal kidney
function.Conﬂicts of interest
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